File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B

TitleFailure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B
Authors
KeywordsActive immunization
Antibody against hepatitis B surface antigen
Immunity
Recurrence
Issue Date2005
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
Journal Of Hepatology, 2005, v. 43 n. 2, p. 283-287 How to Cite?
AbstractBackground/Aims: Lamivudine prophylaxis against hepatitis B virus (HBV) reinfection after liver transplantation is associated with recurrence due to escape mutants. Methods: Fifty-two patients on lamivudine prophylaxis at a median of 412 days (median, 370-2040 days) after transplantation for chronic HBV-related liver disease received two courses of an accelerated schedule of double-dose recombinant HBV vaccine. Before vaccination, all patients were seronegative for HBsAg, anti-HBs and HBV DNA (by qPCR). Three intramuscular doses of vaccine (40 μg each) were administered monthly and another identical course was repeated after 3 months. Lamivudine (100 mg/day) was continued throughout the study. Results: After the first course, two patients developed a weak response (anti-HBs titre of 12 mIU/mL) that disappeared rapidly. One early responder developed anti-HBs (27 mIU/mL) again after the second course but the other did not. Two other patients developed response (anti-HBs titre of 17 and 103 mIU/mL, respectively) giving an overall response rate of 7.7%. The antibody level declined rapidly. At the end of the study, one patient who did not respond had developed viral breakthrough which was treated with adefovir dipivoxil therapy. Conclusions: Active immunization with two courses of double-dose recombinant HBV vaccine has limited efficacy in patients receiving lamividine prophylaxis after liver transplantation. © 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/83271
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChung, MLen_HK
dc.contributor.authorChi, LLen_HK
dc.contributor.authorSee, CCen_HK
dc.contributor.authorLau, GKen_HK
dc.contributor.authorSheung, TFen_HK
dc.date.accessioned2010-09-06T08:39:02Z-
dc.date.available2010-09-06T08:39:02Z-
dc.date.issued2005en_HK
dc.identifier.citationJournal Of Hepatology, 2005, v. 43 n. 2, p. 283-287en_HK
dc.identifier.issn0168-8278en_HK
dc.identifier.urihttp://hdl.handle.net/10722/83271-
dc.description.abstractBackground/Aims: Lamivudine prophylaxis against hepatitis B virus (HBV) reinfection after liver transplantation is associated with recurrence due to escape mutants. Methods: Fifty-two patients on lamivudine prophylaxis at a median of 412 days (median, 370-2040 days) after transplantation for chronic HBV-related liver disease received two courses of an accelerated schedule of double-dose recombinant HBV vaccine. Before vaccination, all patients were seronegative for HBsAg, anti-HBs and HBV DNA (by qPCR). Three intramuscular doses of vaccine (40 μg each) were administered monthly and another identical course was repeated after 3 months. Lamivudine (100 mg/day) was continued throughout the study. Results: After the first course, two patients developed a weak response (anti-HBs titre of 12 mIU/mL) that disappeared rapidly. One early responder developed anti-HBs (27 mIU/mL) again after the second course but the other did not. Two other patients developed response (anti-HBs titre of 17 and 103 mIU/mL, respectively) giving an overall response rate of 7.7%. The antibody level declined rapidly. At the end of the study, one patient who did not respond had developed viral breakthrough which was treated with adefovir dipivoxil therapy. Conclusions: Active immunization with two courses of double-dose recombinant HBV vaccine has limited efficacy in patients receiving lamividine prophylaxis after liver transplantation. © 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhepen_HK
dc.relation.ispartofJournal of Hepatologyen_HK
dc.rightsNOTICE: this is the author’s version of a work that was accepted for publication in Journal of Hepatology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Hepatology, [VOL 43, ISSUE 2, 2005] DOI 10.1016/j.jhep.2005.03.013en_HK
dc.subjectActive immunizationen_HK
dc.subjectAntibody against hepatitis B surface antigenen_HK
dc.subjectImmunityen_HK
dc.subjectRecurrenceen_HK
dc.subject.meshHepatitis B Vaccines - administration and dosage - therapeutic use-
dc.subject.meshHepatitis B virus - genetics - immunology-
dc.subject.meshHepatitis B, Chronic - prevention and control - surgery - virology-
dc.subject.meshReverse Transcriptase Inhibitors - therapeutic use-
dc.subject.meshVaccination-
dc.titleFailure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis Ben_HK
dc.typeArticleen_HK
dc.identifier.emailSee, CC: chanlsc@hkucc.hku.hken_HK
dc.identifier.authoritySee, CC=rp01568en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.jhep.2005.03.013en_HK
dc.identifier.pmid15964658-
dc.identifier.scopuseid_2-s2.0-21844435779en_HK
dc.identifier.hkuros138679en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-21844435779&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume43en_HK
dc.identifier.issue2en_HK
dc.identifier.spage283en_HK
dc.identifier.epage287en_HK
dc.identifier.isiWOS:000230803900013-
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridChung, ML=8696033300en_HK
dc.identifier.scopusauthoridChi, LL=7409789712en_HK
dc.identifier.scopusauthoridSee, CC=7404255575en_HK
dc.identifier.scopusauthoridLau, GK=7102301257en_HK
dc.identifier.scopusauthoridSheung, TF=6506234707en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats